Brief: Medical Marijuana, Inc. Major Investment Company Axim® Biotechnologies Files New U.S. Provisional Patent For Cannabis Gum As A Treatment For Migraine Symptoms
14/05/2019 14:13
May 14 (Reuters) - Axim Biotechnologies Inc AXIM.PK :
* MEDICAL MARIJUANA, INC. MAJOR INVESTMENT COMPANY AXIM®
BIOTECHNOLOGIES FILES NEW U.S. PROVISIONAL PATENT FOR CANNABIS
GUM AS A TREATMENT FOR MIGRAINE SYMPTOMS
Source text for Eikon: ID:nPn8vbhkda
Further company coverage: AXIM.PK
((Briefs@thomsonreuters.com;))
Recent news on Medical Marijuana
See all newsUS Supreme Court rejects medical marijuana firm's bid to avoid racketeering suit (updated)
US Supreme Court rejects medical marijuana firm's bid to avoid racketeering suit
US Supreme Court hears case of trucker fired for failed drug test from cannabis-based CBD
Brief: Medical Marijuana Appoints Dr Timothy Scott as CEO
Brief: Medical Marijuana Inc Reports $9.2 Mln In Net Revenue In 2021 Third Quarter Financial And Operational Results